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THE COST-EFFECTIVENESS OF DIAGNOSTIC
STRATEGIES WITH ANGIOGRAPHY AND/OR
DUPLEX SCANNING FOR AORTOILIAC AND
FEMOROPOPLITEAL ARTERIAL DISEASE
Cofﬁ S, Dijkgraaf M, Ubbink D, Reekers J, Legemate D
Academic Medical Center/University of Amsterdam,
Amsterdam, Netherlands
OBJECTIVES: To assess the cost-effectiveness of three
diagnostic strategies for the aortoiliac (AI) and fem-
oropopliteal (FP) arteries in patients with peripheral arte-
rial occlusive disease (PAOD): angiography (reference),
duplex scanning (DS) plus supplementary angiography 
if DS is inconclusive, and DS plus conﬁrmative angio-
graphy if DS is positive. METHODS: Incremental cost-
effectiveness analysis from a provider perspective with the
identiﬁcation of a signiﬁcant (positive) or insigniﬁcant
(negative) diameter reduction (= the number of identiﬁed
cases) as the primary effect parameter. Sensitivity (AI:
0.86–0.91; FP: 0.80–0.85) and speciﬁcity (AI: 0.97–0.99;
FP: 0.96–0.98) data of DS were derived from a meta-
analysis. The real costs of both diagnostic modalities were
calculated from the associated personnel, material and
overhead costs at our hospital for the year 2000. Costs
were expressed in euro. RESULTS: The costs of DS were
€67.20 and €63.28 for the AI and FP tract respectively.
The cost of angiography (including a one-day admission)
was €503.10. The reference strategy resulted in an unam-
biguous diagnosis in 90% of the AI as well as FP cases
compared with 89% (AI) and 85% (FP) for the supple-
mentary strategy. Assuming the disease prevalence in the
laboratory between 70–90% however, the extra costs 
per identiﬁed case for the reference strategy compared
with the supplementary strategy ranged from €59.000–
€14.000 for the AI tract and from €8.300–€5.100 for the
FP tract. CONCLUSIONS: The reference strategy is most
effective for both, the AI and FP tracts. If society does not
want to spend over €10,000 per identiﬁed case, then for
the AI tract the supplementary strategy is the most cost-
effective one. If society is willing to spend €10,000 per
identiﬁed case, then one should prefer the reference strat-
egy for the FP tract.
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PROBABILISTIC SENSITIVITY ANALYSIS FOR
EVALUATING COST-EFFECTIVENESS IN
SECONDARY PREVENTION OF ISCHEMIC
EVENTS
Lennes X1, Carita P2, Gabriel S2
1Cresge-Labores Lille University, Lille, France; 2Sanoﬁ-
Synthelabo, Bagneux, France
OBJECTIVES: In the case of a determinist cost-
effectiveness analysis (CEA), uncertainty related to the
parameters can be handled by a probabilistic sensitivity
analysis for estimating conﬁdence interval (CI) for incre-
mental cost-effectiveness ratio (ICER). The study aim was
to assess uncertainty in a CEA from a French perspective
of two strategies in secondary prevention of ischemic
events: clopidogrel versus aspirin. METHODS: From a
Markov model based on CAPRIE trial (Clopidogrel
versus Aspirin in Patients at Risk of Ischemic Events
19185 patients), a CEA was run in order to assess the
cost per life year saved with clopidogrel versus aspirin.
We supposed that each of the parameters of the model,
instead of taking a single value, was a random variable
to which a distribution could be associated: beta distrib-
ution was used in the generation of transition probabili-
ties (the parameters of distribution depend on the study
characteristics from which the parameters issue) and tri-
angular distribution of unit cost. Using a Monte-Carlo
simulation, the joint distribution of mean incremental
cost and mean incremental effectiveness were simulated
and displayed in the cost-effectiveness plan. Ninety ﬁve
percent conﬁdence intervals were estimated using per-
centile method. RESULTS: The results of the Monte-
Carlo simulation (10000 replications) were all clustered
in the quadrant corresponding to the situation where
clopidogrel is more effective and more expensive. For a
hypothetical cohort of 1000 patients treated during 2
years, the estimation of the additional cost was equal to
€1041 per patient CI = [952; 1,130], number of life years
gained to 0,068 per patient (CI = [0,046; 0,094]). The
ICER was equal to €15,907 CI = [11,655; 21,067]. CON-
CLUSION: Conﬁdence intervals estimated from the prob-
abilistic sensitivity analysis were not too wide. This
suggested that the CEA is robust and provides reliable
data for decision-makers. Within its conﬁdence interval,
the ICER remains within acceptable range, and compares
favourably with other therapeutic strategies.
PCV31
ACCEPTANCE AND RELIABILITY OF A COST-
MEASUREMENT QUESTIONNAIRE IN CARDIAC
REHABILITATION
Schweikert B1, Hahmann HW2, Leidl R1
1University of Ulm, Ulm, Germany; 2Klinik Schwabenland,
Isny-Neutrauchburg, Germany
OBJECTIVES: Comprehensive measurement of disease
related cost in an outpatient setting is a crucial task for
economic assessment. In decentralized health systems like
in Germany provider or third party payer data are not
readily accessible suggesting a patient oriented approach.
Objective of this pilot study was to develop a retrospec-
tive cost measurement instrument for cardiac rehabilita-
tion patients which would allow reliable and—compared
to prospective measurement—time and resource saving
assessment of cost in studies with a medium to long-term
time horizon. METHODS: A cost questionnaire was
developed covering medical and non-medical resource use
retrospectively over a 12-week time period after discharge
from inpatient cardiac rehabilitation. One hundred and
six patients were included in the pilot study (mean 
age 55, male 85%, myocardial infarction 51%, bypass
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surgery 42%). The questionnaire was sent out twelve
weeks after discharge and covered the period since. Reli-
ability was assessed by comparing the 12-week question-
naire with a cost diary which patients were asked to ﬁll
in prospectively during the ﬁrst 4 weeks after discharge.
RESULTS: The 3-month questionnaire showed a re-
sponse rate of 88%. Ninety two percent of respondents
found the questionnaire easy or very easy to ﬁll in. Rate
of completion was close to 100% for all items. Time for
completion took on average 27 minutes. Comparison
with the data collected by the prospective cost diary
showed modest to good correlation for the overlapping
period. Intraclass correlation coefﬁcients ranged from
0.57 (cost of daily drug intake) to 0.9 (hospital days).
CONCLUSIONS: The instrument showed good accep-
tance and feasibility as well as reasonable reliability when
compared to a detailed prospective cost diary. Therefore
the instrument appears to be an efﬁcient alternative for
patient oriented cost measurement. With respect to relia-
bility further suggestions for improvement of the instru-
ment were developed where indicated.
PCV32
THE USE OF STATINS IN SECONDARY CARE:
EVIDENCE FROM ACTUAL PRACTICE DATA
Degli Esposti L1, Degli Esposti E2,Valpiani G1, Saragoni S1
1CliCon Srl—Health, Economics and Outcomes Research,
Ravenna, Italy; 2Ravenna Local Health Unit, Ravenna, Italy
OBJECTIVE: To perform a pharmacoepidemiologic
analysis on the utilization and cost of statins in secondary
care practice in non-experimental setting. METHODS:
The Ravenna Local Health Unit administrative database
(approximately 350,000 subjects) was used to perform 
a registry of Acute Myocardial Infarction (AMI) since
1996. The registry was made by the linkages among
patients’ baseline characteristics, hospital admissions and
drug prescriptions. A 6-month follow-up study included
all subjects discharged alive from the hospital after AMI
during the period 1996–2000. Patients with previous
AMI since 1991 and those not in the province’s databases
for the entire follow-up were excluded. Drug prescrip-
tions data were processed for statins (ATC Code C10A),
ACE-inhibitors (C09A even if associated with C09B),
beta-blockers (C07), other antihypertensives (C02, C03,
C08, C09C and C09D), as well as for aspirin (B01AC06),
antidiabetic drugs (A10A and A10B), cardiac drugs (C01)
and other antiaggregants (B01AA and B01AB,
B01AC05). Drug cost was evaluated at NHS purchase
prices. RESULTS: A total of 2265 subjects were enrolled
(446 in 1996, 440 in 1997, 443 in 1998, 443 in 1999,
and 493 in 2000). The percentage of patients prescribed
for statins increased each year (from 22.6% in 1996 to
43.8% in 2000) as well as the percentage of those pre-
scribed for aspirin (from 48.0% in 1996 to 80.5% in
2000) and beta-blockers (from 27.4% in 1996 to 41.0%
in 2000). Overall cost for statins accounted to €10,610
in 1996, €15,344 in 1997, €23,483 in 1998, €35,910 in
1999, and €45,103 in 2000. Average cost for patients pre-
scribed for statins ranged from €105.05 in 1996 to
€208.81 in 2000 and increased over each year. CON-
CLUSIONS: Evidence from secondary care practice in the
province of Ravenna highlights a trend for more frequent
use of statins, aspirin and beta-blockers after discharge
for AMI.
PCV33
COST-EFFECTIVENESS OF METHODS TO QUIT
SMOKING IN FINNISH HEALTH CARE
Jormanainen VJ, Hahl J
GlaxoSmithKline Oy, Espoo, Finland
OBJECTIVES: The Finnish Health For All 2000 target
set in the mid-1980s (at least 80% non-smoking) was not
realised. Actually, prevalence of smoking has remained
rather constant during the 1990s even after introduction
of over-the-counter nicotine replacement (NRT) options.
Our intent was to model cost-effectiveness of six methods
(willpower, physician advice, NRT [patch, gum, spray],
bupropion) to quit smoking as applied in Finnish health
care. METHODS: Data on efﬁcacy (% successfully quit
smoking during 12 months’ observation period) were
obtained from published meta-analyses and original arti-
cles. Cost data included only direct costs (physician visits,
medications, adverse events [occurrence 1% in each treat-
ment]). Costs were estimated using societal perspective (in
year 2000 Euros). Decision-tree based average cost-
effectiveness estimates (€/additional quitter) and incre-
mental cost-effectiveness ratios (ICER) were derived by
using Data 3.5 software. Two-way sensitivity analyses
were performed. RESULTS: Efﬁcacy of willpower (1%)
and physician advice (3%) were the lowest, followed by
NRT patch (13%) and NRT gum (18%) whereas higher
for NRT spray (24%) and bupropion (30%). Costs of
willpower were set to zero by deﬁnition. Cost per addi-
tional quitter of bupropion (€954) treatment was the
lowest, and NRT spray (€2397) the highest. Bupropion
dominated over NRT gum and spray. ICER of NRT patch
vs. physician advice was €1495 (€804 for bupropion)
whereas ICER of bupropion vs. NRT patch was €404.
Sensitivity analyses showed results were robust. CON-
CLUSIONS: Short-term decision-tree analysis suggests
that bupropion is a cost-effective option for physicians in
order to help motivated smokers to quit smoking in
Finnish health care settings.
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COST-EFFECTIVENESS OF PATHOGEN
INACTIVATION FOR PLATELET TRANSFUSIONS
IN DUTCH CARDIAC SURGERY
Postma MJ1, de Wolf JT2, van Hulst M1, Staginnus U3,
Smit Sibinga CT4
1Groningen University Institute for Drug
Exploration/university of Groningen Research Institute of
Pharmacy (GUIDE/GRIP), Groningen, Netherlands; 2University
Hospital Groningen, Groningen, Netherlands; 3Baxter, S.L,
Madrid, Spain; 4Sanquin, Amsterdam, Netherlands
